EyePoint Pharmaceuticals Reports Q2 Revenue and Provides Corporate Update

Published on August 7, 2025
WATERTOWN, Mass.—EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a pharmaceutical company focused on developing and commercializing ophthalmic products for treating retinal diseases, announced financial results for the second quarter ended June 30, 2025, and highlighted recent corporate developments. Revenue for the second quarter was $5.3 million, a decline from $9.5 million in the same quarter last year, according to the announcement. The company also reported a net loss of $59.4 million in the second quarter, compared with a net loss of $30.8 million in the corresponding period of 2024.
Continue reading on website
Other news

Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz

August 6, 2025
With FDA approval of LENZ Therapeutics’ Vizz (LNZ100), optometrists now have a daily, non-invasive treatment option for presbyopia, giving patients more freedom and clinicians greater flexibility in care.

How can myopia be controlled when only a small percentage of doctors attempt to control it?

August 7, 2025
Specialty care is always needed in any field, and myopia control is no exception.